Perfromance Wealth Partners LLC Has $275,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Perfromance Wealth Partners LLC trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 17.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,710 shares of the medical research company’s stock after selling 802 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in Edwards Lifesciences were worth $275,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of EW. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. raised its position in Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after buying an additional 2,606,950 shares during the last quarter. Seilern Investment Management Ltd purchased a new stake in Edwards Lifesciences in the 4th quarter valued at $109,490,000. Finally, Nordea Investment Management AB raised its position in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after buying an additional 1,043,484 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EW. Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Truist Financial reissued a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Stifel Nicolaus increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Stock Up 0.2 %

Shares of NYSE EW opened at $69.94 on Wednesday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50-day simple moving average of $72.12 and a two-hundred day simple moving average of $71.03. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $41.25 billion, a P/E ratio of 10.09, a P/E/G ratio of 3.58 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the firm posted $0.59 EPS. The company’s revenue was up 8.9% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 in the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.